Full-Time

Salesforce PRM & CPQ Expert

Posted on 12/13/2025

Agilent Technologies

Agilent Technologies

10,001+ employees

Provides eProcurement automation and hosted catalogs

Compensation Overview

$116.8k - $219k/yr

+ Bonus + Stock

Company Does Not Provide H1B Sponsorship

Remote in USA + 1 more

More locations: Remote in India

Remote

Category
Business & Strategy (2)
,
Required Skills
Data Structures & Algorithms
Salesforce
Data Analysis
Requirements
  • Bachelor’s or Master’s degree in Business, Information Systems, or related field.
  • 8+ years of experience leading Salesforce PRM, CPQ, and CRM initiatives in complex, global environments.
  • Proven track record supporting Mergers & Acquisitions, including system consolidation, data harmonization, and integration planning.
  • Deep understanding of Salesforce Experience Cloud (PRM), Sales Cloud (CRM), and Salesforce CPQ.
  • Strong collaboration skills with IT, Finance, Marketing, and Product teams to deliver scalable business solutions.
  • Experience integrating Salesforce with ERP, Marketing Automation, and Analytics platforms.
  • Exceptional stakeholder management, communication, and executive influencing skills.
  • Demonstrated ability to learn and adapt quickly in evolving technology environments.
Responsibilities
  • Strategic Ownership: Serve as the business owner and subject-matter expert (SME) for Salesforce PRM, CPQ, and CRM capabilities globally.
  • Strategic Ownership: Define and own the Salesforce roadmap for partner, quoting, and customer engagement platforms aligned with commercial priorities and digital transformation goals.
  • Strategic Ownership: Represent the voice of the business in all Salesforce-related design, architecture, and governance forums to ensure usability, scalability, and adoption.
  • Strategic Ownership: Collaborate with IT, Architecture, and Data teams to ensure solutions align with enterprise standards, data strategy, and security compliance.
  • Strategic Ownership: Lead post-merger technology assessments to identify overlaps, integration opportunities, and transition strategies for newly acquired platforms.
  • Salesforce PRM Leadership: Lead the design and continuous improvement of the Salesforce PRM portal (Experience Cloud) to enhance partner collaboration, onboarding, and enablement.
  • Salesforce PRM Leadership: Streamline partner lifecycle processes — deal registration, incentives, co-marketing, and content access.
  • Salesforce PRM Leadership: Develop dashboards and analytics to measure partner contribution, engagement, and ROI.
  • Salesforce PRM Leadership: Collaborate with Channel Sales, Partner Marketing, and Operations to automate partner communications and improve partner satisfaction.
  • Salesforce CPQ Enablement: Own the Salesforce CPQ process end-to-end: configuration, pricing, discounting, approvals, and quote-to-order integration.
  • Salesforce CPQ Enablement: Collaborate with Product Management, Finance, and IT to ensure pricing accuracy, margin control, and catalog consistency.
  • Salesforce CPQ Enablement: Standardize global quoting workflows to improve speed, compliance, and operational governance.
  • Salesforce CPQ Enablement: Integrate CPQ seamlessly with Salesforce CRM, PRM, and ERP systems for a unified quote-to-cash process.
  • Salesforce CRM Integration: Ensure alignment of Salesforce Sales Cloud (CRM) with PRM and CPQ to provide a 360° view of customer and partner data.
  • Salesforce CRM Integration: Partner with IT and Marketing to integrate Salesforce with ERP, Marketing Automation (Marketo, Pardot), and Analytics tools.
  • Salesforce CRM Integration: Support global sales operations through the creation of actionable dashboards, workflows, and data structures that drive accountability and insight.
  • Integration, Collaboration & M&A: Work in close partnership with IT delivery teams to translate business requirements into technical designs and scalable Salesforce solutions.
  • Integration, Collaboration & M&A: Define and manage system integrations between Salesforce PRM, CPQ, CRM, and third-party or newly acquired applications.
  • Integration, Collaboration & M&A: Lead post-acquisition system evaluation, data migration, and harmonization efforts to ensure seamless business continuity.
  • Integration, Collaboration & M&A: Act as the bridge between Business and IT, ensuring technology execution supports business strategy through evolving tech landscapes.
  • Integration, Collaboration & M&A: Continuously learn and adapt to new technologies introduced through M&A or platform evolution.
  • Continuous Improvement: Establish success metrics and dashboards for adoption, data accuracy, and performance across Salesforce PRM, CPQ, and CRM.
  • Continuous Improvement: Lead global user enablement and communication programs to drive adoption and change readiness.
  • Continuous Improvement: Stay current on Salesforce releases, partner ecosystem innovations, and new technology integrations emerging through M&A
Desired Qualifications
  • Experience applying AI, automation, and predictive analytics within Salesforce is a plus

Agilent Technologies provides eProcurement services that help businesses buy supplies more efficiently. It offers a suite of electronic procurement tools that let clients load their pricing into existing purchasing platforms, access a hosted catalog, and complete transactions digitally without paper. The service connects pricing data to clients’ procurement systems, delivers an online catalog, and supports automated, paperless purchasing workflows. This makes purchasing faster and reduces manual steps. Compared with competitors, Agilent emphasizes automation, quick connectivity between pricing, catalogs, and purchasing platforms, and a reliable, scalable experience backed by its broad product range. The company aims to improve client productivity and lower procurement costs, helping customers buy what they need more easily while keeping prices clear and consistent.

Company Size

10,001+

Company Stage

IPO

Headquarters

Santa Clara, California

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • Replacement cycles are driving upgrades in aging laboratory fleets.
  • Biologics QC demand supports MAM and OpenLab workflow adoption.
  • New platforms like 9500 ICP-MS expand high-value instrument revenue.

What critics are saying

  • Revenue misses have occurred multiple times over the past two years.
  • Replacement-cycle tailwinds fade after backlog upgrades are completed.
  • China spending slowdowns and sourcing restrictions hit sales and operations.

What makes Agilent Technologies unique

  • Agilent sells instruments, software, consumables, and services across 110 countries.
  • Its solutions target regulated life sciences, diagnostics, and applied chemical markets.
  • OpenLab, CrossLab, and new workflows deepen software and service attachment.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Agilent Technologies who can refer or advise you

Benefits

Remote Work Options

Performance Bonus

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-4%
Yahoo Finance
Apr 3rd, 2026
Agilent loses CRISPR patent case but launches BioTek Cytation 9 imaging platform

Agilent Technologies faces a CRISPR patent setback after the Supreme Court denied its petition in March 2026, whilst simultaneously launching the BioTek Cytation 9, a cell imaging multimode reader combining high-content imaging with microplate reading. The patent loss appears more reputational than financial. The company's investment case relies on steady demand for laboratory tools and diagnostics across pharmaceutical and biotech sectors, supported by recurring revenue. The Cytation 9 launch reinforces Agilent's push into higher-value, automation-friendly platforms that could deepen relationships with research labs. Analysts project $8.6 billion revenue and $2 billion earnings by 2029, with a fair value estimate of $163.19 representing 41% upside. However, tariff-driven supply chain costs pose ongoing margin pressure risks, with community fair value estimates ranging from $125 to $163 per share.

Business Wire
Mar 26th, 2026
Agilent receives FDA approval for PD-L1 IHC 22C3 pharmDx in esophageal or GEJ carcinoma

Agilent Technologies has received US Food and Drug Administration approval for PD-L1 IHC 22C3 pharmDx as a companion diagnostic to identify patients with oesophageal or gastroesophageal junction carcinoma eligible for treatment with Merck's KEYTRUDA. The diagnostic identifies patients whose tumours express PD-L1 with a Combined Positive Score of at least 1. This marks the eighth FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx for use with KEYTRUDA. The diagnostic is also approved for identifying eligible patients with non-small cell lung cancer, cervical cancer, triple-negative breast cancer and several other cancer types. Oesophageal cancer caused approximately 16,250 deaths in the United States in 2025, with a five-year relative survival rate of 21.9%. The diagnostic was developed by Agilent in partnership with Merck.

Yahoo Finance
Mar 23rd, 2026
Agilent leads research tools stocks with $1.8B Q4 revenue, up 7% amid sector decline

Bio-Techne led research tools and consumables stocks in Q4 earnings performance, according to an analysis of the sector. The 10 companies tracked reported a satisfactory quarter overall, with revenues beating analyst consensus estimates by 1.2%, whilst next quarter's revenue guidance met expectations. However, share prices have struggled, falling an average of 19.5% since the latest earnings results. Agilent Technologies delivered the weakest performance against analyst estimates in the group. The company reported revenues of $1.80 billion, up 7% year on year, meeting analyst expectations. Despite beating revenue guidance for next quarter, Agilent's stock has fallen 9.4% since reporting and currently trades at $112.94. The sector faces challenges including high R&D costs and vulnerability to research funding fluctuations, whilst benefiting from growing demand in synthetic biology and personalised medicine.

GS MedTech
Mar 9th, 2026
Agilent Technologies acquires US firm BioTek Instruments

Agilent Technologies has completed the acquisition of US-based BioTek Instruments for around $1.165bn (£929m).In July, Agilent first signed an agreement to acquire BioTek Instruments, which is involved in the designing, manufacturing, and distribution of advanced life science instrumentation.Agilent also said that the net purchase price is expected to be around $1.05bn (£837m), with anticipated t

Agilent Technologies
Mar 9th, 2026
Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions

Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP, in an all-cash transaction valued at $950 million.  Biocare is a high-growth global pathology antibody leader, serving customers with a complementary portfolio of immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions designed to support improved patient health outcomes across oncology and broader clinical pathology. With more than 300 specialized antibodies and a proven R&D capability, Biocare has achieved annual double-digit revenue and profit growth since 2021 and generated over $90 million in revenue in 2025. “The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth through customer-centric innovation and disciplined capital allocation,” said Agilent President and CEO Padraig McDonnell. “Together, this complementary combination will enable us to better serve our valued pathology customers across clinical and research settings, accelerate innovation and support long-term value creation for our shareholders.” “The acquisition by Agilent is an exciting milestone for Biocare,” said Luis de Luzuriaga, CEO of Biocare. “By joining Agilent and combining our complementary capabilities in cancer diagnostics, we will expand our operational scale, accelerate innovation and enhance the level of service we provide to customers and partners – ultimately benefiting the patients we serve. After years of significant progress, this is the right time to move forward with new ownership aligned with our commitment to product quality, clinical impact and value creation. I would like to thank our investors, Excellere Partners and GHO Capital, whose support and counsel have been instrumental in building Biocare into the company it is today.” In a joint statement, Ryan Glaws and Mike Mortimer, Managing Partners at Excellere Partners and GHO Capital, respectively, said, “Working closely with Luis and the Biocare management team, we have been proud to support their significant growth and success by applying our tried and tested growth playbook and leveraging our deep expertise and network in life science tools and diagnostics to build the company into the successful global business it is today. With its exceptional team and strengthened capabilities, Biocare has developed into a recognized leading innovator in IHC solutions, improving the diagnosis and treatment of patients. As Biocare continues its growth trajectory, we are pleased to have found the right partner in Agilent – one that can utilize its global reach and resources to unlock even greater market access, enhanced customer support and accelerated innovation for Biocare’s customers worldwide.” Strategic and Financial Benefits of the Transaction

INACTIVE